14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment
- PMID: 32020360
- DOI: 10.1007/s10620-020-06115-7
14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment
Abstract
Background: Amoxicillin, metronidazole, proton pump inhibitor, bismuth quadruple therapy had been shown to reliably achieve high eradication rates. The role of individual components remains undefined.
Aim: To identify the additional benefit/role of bismuth in amoxicillin, metronidazole, proton pump inhibitor, bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment.
Methods: This was a non-inferiority factorial design trial. Treatment-naive H. pylori-infected subjects were randomly (1:1) assigned to receive 14-day amoxicillin- and metronidazole-containing triple therapy consisting of esomeprazole 20 mg twice a day, amoxicillin 1 g, and metronidazole 400 mg both thrice daily with or without 220 mg bismuth twice a day. Six weeks after treatment, H. pylori eradication was assessed by 13C-urea breath test. Antimicrobial susceptibility was assessed by the twofold agar dilution method.
Results: From July 2018 to June 2019, a total of two hundred and sixteen subjects were randomized. Both therapies achieved high eradication rates. Per-protocol with bismuth = 97.9% (94/96, 95% CI 95.1-100%) and without bismuth = 94.7% (90/95, 95% CI 90.3-99.1%) (P = 0.43). Intent-to-treat analysis = 90.7% (98/108, 95% CI 85.2-96.2%) versus 88.9% (96/108, 95% CI 82.8-95.0%) with and without bismuth (P = 0.65). The two regimens were not inferior by intent-to-treat or per-protocol analyses. Metronidazole resistance did not affect the efficacy of either therapy.
Conclusion: Neither the presence nor absence of bismuth or metronidazole resistance reduced the effectiveness of triple therapy containing esomeprazole 20 mg twice a day, amoxicillin 1 g, and metronidazole 400 mg thrice daily in this population. The clinical trial was registered with ClinicalTrials.gov, NCT03557437.
Keywords: Amoxicillin; Bismuth; Helicobacter pylori; Metronidazole; Triple therapy.
Similar articles
-
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18. Lancet. 2016. PMID: 27769562 Clinical Trial.
-
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.Helicobacter. 2018 Jun;23(3):e12485. doi: 10.1111/hel.12485. Epub 2018 Apr 25. Helicobacter. 2018. PMID: 29696736 Clinical Trial.
-
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.Aliment Pharmacol Ther. 2019 Jun;49(11):1385-1394. doi: 10.1111/apt.15273. Epub 2019 Apr 24. Aliment Pharmacol Ther. 2019. PMID: 31020673 Clinical Trial.
-
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.Expert Rev Anti Infect Ther. 2018 Sep;16(9):679-687. doi: 10.1080/14787210.2018.1511427. Epub 2018 Aug 23. Expert Rev Anti Infect Ther. 2018. PMID: 30102559 Free PMC article. Review.
-
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548. World J Gastroenterol. 2018. PMID: 30386104 Free PMC article. Review.
Cited by
-
Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.Clin Gastroenterol Hepatol. 2022 May;20(5):973-983.e1. doi: 10.1016/j.cgh.2021.03.026. Epub 2021 Mar 26. Clin Gastroenterol Hepatol. 2022. PMID: 33775895 Free PMC article. Review.
-
Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies.Gastroenterology. 2021 Nov;161(5):1433-1442.e2. doi: 10.1053/j.gastro.2021.07.012. Epub 2021 Jul 19. Gastroenterology. 2021. PMID: 34293298 Free PMC article.
-
Comparison of Risk and Severity of Helicobacter Pylori Infection in Non-Native Versus US Native Pediatric Patients.JPGN Rep. 2023 Jun 28;4(3):e331. doi: 10.1097/PG9.0000000000000331. eCollection 2023 Aug. JPGN Rep. 2023. PMID: 37600603 Free PMC article.
-
Eradication of Helicobacter pylori: a prospective comparative randomized trial of standard versus optimized quadruple therapy.Future Sci OA. 2024 May 15;10(1):FSO974. doi: 10.2144/fsoa-2023-0316. eCollection 2024. Future Sci OA. 2024. PMID: 38817354 Free PMC article.
-
Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis.Pathogens. 2022 Jul 12;11(7):786. doi: 10.3390/pathogens11070786. Pathogens. 2022. PMID: 35890031 Free PMC article. Review.
References
-
- El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:992–1002.
-
- Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report. Gut. 2017;66:6–30. - PubMed
-
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239. - PubMed
-
- Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51–69. - PubMed
-
- Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin N Am. 2015;44:537–563.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical